Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Of India Awaits U.S. Court Ruling On Fate Of Lipitor Generic

This article was originally published in PharmAsia News

Executive Summary

India's Ranbaxy Laboratories expects to learn this week whether it can launch a generic on the U.S. market of local drug-maker Pfizer's Lipitor (atorvastatin) the world's best-selling drug

You may also be interested in...



Pfizer Will Not Launch EU Adalimumab

Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.

New Arthroscopy Tubing Guidance Aims To Reduce Cross-Contamination

Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.

WHO Refines Approach For Listing Products In Health Emergencies

A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies. 

UsernamePublicRestriction

Register

SC077990

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel